These 6 charts show how NIH research funding has been reshaped under Trump
- The Trump administration reshaped U.S. biomedical research by implementing funding cuts and delays to National Institutes of Health (NIH) grants.
- These delays impacted long-term grants that are typically awarded for multiple years and paid out annually to cover lab work and staff.
- Funding instability threatens the employment of lab workers and the delivery of medical care for patients participating in clinical trials.
Sources & Citations
1 sourceMore Stories
Trump’s nominee to lead FDA questioned on vaccines, abortion in Senate hearing
• FDA nominee Dr. Heidi Overton testified before the Senate on Thursday regarding her views on vaccines and abortion. • Dr. Overton stated that the MMR vaccine is safe, effective, and "not lethal," contradicting previous claims made by President Trump.
Read original · cnn.com
CNNMedicare Advantage and Medicare Prescription Drug Programs Expected to Remain Stable in 2027
• The Centers for Medicare & Medicaid Services announced that Medicare Advantage and Medicare Prescription Drug Programs are expected to remain stable in 2027. • Weighted average Medicare Advantage premiums are projected to fall more than 16% from 2026 to 2027, while average prescription drug premiums in those plans are expected to drop 38%.
Read original · cms.govHospitals in England hit by shortages of common drugs such as paracetamol | Hospitals
• Hospitals in England are experiencing shortages of common medications, including paracetamol, co-codamol, and the blood pressure drug ramipril. • The health department issued serious shortage protocols to ensure patients can still access ramipril despite its limited supply.
Read original · theguardian.comNanoViricides, Inc. (NASDAQ:NNVC) |
• NanoViricides, Inc. filed its Annual Report on Form 10-K with the SEC, detailing the progress of its antiviral drug NV-387. • The company is conducting Phase II trials for NV-387 to treat Mpox and Ebola, noting that there is currently no approved drug for Mpox Clade I or Clade II.
Read original · finanzwire.comTop U.S. Health Officials to Address Rare Disease Leaders at 2026 NORD Breakthrough Summit in Washington, D.C.
• Three top U.S. federal health officials will join over 900 rare disease leaders at the 2026 NORD Rare Diseases and Orphan Products Breakthrough Summit from October 25–27 in Washington, D.C. • Attendees will include Kyle Diamantas, the Acting Commissioner of Food and Drugs at the U.S. Food and Drug Administration.
Read original · prnewswire.comNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - BioSpace
• NanoViricides, Inc. filed its annual report detailing the Phase II clinical trials for NV-387, a broad-spectrum antiviral drug. • The company is targeting unmet medical needs for MPox and Ebola, noting that no approved drugs currently exist for the treatment of MPox Clade I or Clade II.
Read original · biospace.comFDA nominee Heidi Overton hearing: Vaccines, vapes, and China
• Senators questioned FDA nominee Heidi Overton during a hearing regarding her positions on vaccines, vapes, and abortion. • Overton frequently avoided giving direct answers to the senators' questions during the session.
Read original · statnews.com
StatnewsGastein health conference gets underway – POLITICO
• The European Commission adopted a proposal on Monday for a Council recommendation to combat cardiovascular diseases. • These heart-related conditions are the leading cause of death in Europe, claiming 1.7 million lives annually.
Read original · politico.euMedical News Publisher
• A phase 3 clinical trial found that delivering focused radiation therapy over three to five sessions after brain metastasis surgery reduced cancer recurrence compared to a single session. • This study represents the first randomized trial to directly compare these two specific radiation delivery schedules.
Read original · newswise.comPAHO marks 50 years of strengthening health emergency preparedness and response in the Americas - PAHO/WHO
• The Pan American Health Organization (PAHO) marked the 50th anniversary of its Health Emergencies Program on September 28, 2026. • Regional coordination mechanisms were activated within hours to support national and international responses after two powerful earthquakes struck Venezuela in June 2026.
Read original · paho.orgThe Americas are making progress in health but must accelerate action on emerging challenges, says PAHO Director - PAHO/WHO
• Dr. Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), called for accelerated action on emerging health challenges during the opening of the 63rd Directing Council. • The Director identified primary health care, vaccination, digital health, and emergency preparedness as the region's top priorities.
Read original · paho.org